In September, the drug safety genetic testing manufacturer "Shiji Biomedical" accused the Academia Sinica of arbitrarily investing the company's patented drug genetic testing technology into the "Taiwan Precision Medicine Initiative (TPMI)", and claimed 300 million yuan from the Academia Sinica, and pointed out that Guo Peien, the person in charge of the project and director of the Institute of Biomedical Sciences of the Academia Sinica, had intended to settle before the trial. Liu Fudong (third from right), the vice president of the Academia Sinica, confirmed that Guo Peien had indeed proposed a settlement in the past.
(Photo by reporter Yang Yuanting)
[Reporter Yang Yuanting/Taipei Report] Medication safety genetic testing manufacturer "Shiji Biomedical", in September, accused Academia Sinica of arbitrarily investing the company's patented technology of drug genetic testing in "Taiwan Precision Medicine Initiative (TPMI)" and reported to Academia Sinica Claimed 300 million yuan, and pointed out that Guo Peien, the person in charge of the project and director of the Institute of Biomedical Sciences of the Academia Sinica, had intended to settle before the trial. Liu Fudong, vice president of the Academia Sinica, confirmed today (23rd) that Guo Peien had indeed proposed a settlement in the past, but now the whole case has entered Litigation procedures, so it depends on the litigation process.
On September 14th, the up-and-coming company Shiji Biomedical and Academia Sinica filed a lawsuit for the first time. Shiji Biomedical claimed that the technology used in the TPMI project of Academia Sinica has infringed the company's patents, and pointed out that TPMI used the plan for free. Called for academic research, but never notified Shiji, and proposed a compensation amount of 300 million yuan to the Academia Sinica. The weekly reported at the time that the project executor, Guo Peien, director of the Academia Sinica's Institute of Biomedical Sciences, had hoped for a settlement.
Please read on...
The Legislative Yuan Education and Culture Committee is reviewing the Academia Sinica’s next year’s budget. Liu Fudong, who supervises the field of biomedicine, asked the media about the Academia Sinica’s suspected infringement of Shiji Biomedical. And why the manufacturer would claim that the Academia Sinica is infringing, and said "I can't comment on this", and pointed out that the legislators are also very concerned, some things can be clarified, and some things have to wait for the procedure; when asked why such a dispute with the manufacturer occurred, he said, "It is This will be clarified later.”
When asked whether it would affect the implementation of TPMI's follow-up plan, Liu Fudong said, "I will answer later." The whole thing was done by TPMI itself, but was later asked by the reporter whether it meant that the TPMI plan had nothing to do with Academia Sinica?
He also said that of course it was done by Academia Sinica, but he also pointed out that he could not comment at this time.
When asked if Guo Peien ever wanted to settle with the manufacturer, Liu Fudong initially said, "The details will become clear later." Then he was asked whether Guo Peien had proposed a settlement with the manufacturer, and whether the whole matter was true or false. Said, "There may have been a chance for reconciliation in the past", that is, of course reconciliation was possible, but now that the lawsuit has been filed, it depends on the process.
"
Shiji Biomedical claimed that the technology used by Academia Sinica's TPMI project has violated the company's intellectual property rights, and pointed out that TPMI actually used the project as a free call for academic research, and never notified Shiji, and proposed 3 to Academia Sinica The amount claimed in billions of dollars.
(file photo)